Clinical Trials Logo

Lupus Erythematosus, Systemic clinical trials

View clinical trials related to Lupus Erythematosus, Systemic.

Filter by:

NCT ID: NCT03771885 Not yet recruiting - Clinical trials for Lupus Erythematosus, Systemic

BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

Start date: January 16, 2019
Phase: Phase 1
Study type: Interventional

The main objective of this study is to assess the safety, tolerability and pharmacokinetics of orally administered BI 705564 in patients with systemic lupus erythematosus

NCT ID: NCT03762824 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease

IPS-BOOSTER
Start date: June 14, 2016
Phase: Phase 4
Study type: Interventional

The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on antibody response elicited by pneumococcal vaccination using 13-valent conjugate vaccine in combined schedules with 23-valent polysaccharide vaccine. In addition, the aim is to study the clinical aspects of vaccination regarding: tolerability in immunosuppressed patients with IRD, impact on existing rheumatic disease, possible association with onset of new autoimmune diseases, long-term immunity following pneumococcal vaccination and efficacy in preventing invasive pneumococcal disease. Results from this study are expected to bridge the existing knowledge gap and contribute to body of evidence needed for recommendations and implementation of vaccination program in IRD patients.

NCT ID: NCT03757065 Not yet recruiting - Multiple Sclerosis Clinical Trials

Cell Surface Marker Expression in Autoimmune Diseases

CASCADE
Start date: January 7, 2019
Phase:
Study type: Observational

This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's disease, (f) ulcerative colitis and (g) inflammatory myositis.

NCT ID: NCT03752983 Not yet recruiting - Systemic Lupus Clinical Trials

Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE

Start date: December 15, 2018
Phase:
Study type: Observational

Systemic lupus erythematosus (SLE) is systemic autoimmune disease characterized by various immunological abnormalities, including dysregulated activation of both T and B lymphocytes with overt production of autoreactive antibodies.The chemokine CXC ligand 13 protein (CXCL13), also known as B cell-attracting chemokine-1 (BAC-1) or B lymphocyte chemoattractant (BLC), CXCL13 serum levels were correlated with disease activity using the SLE Disease Activity Index (SLEDAI) and to lupus nephritis

NCT ID: NCT03749044 Recruiting - Pre-Eclampsia Clinical Trials

ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies

Start date: May 28, 2018
Phase: N/A
Study type: Interventional

Preeclampsia is a serious maternal condition affecting up to 5% of pregnancies from the general population and up to 30% of lupus pregnancies. Aspirin (acetylsalicylic acid- ASA) has been shown to reduce the risk of preeclampsia, by half, in women at high risk. Therefore, it is recommended that health professionals initiate aspirin early during pregnancy in women with lupus. Despite this recommendation, there are currently no studies of aspirin in women with lupus for this indication. This is a critical knowledge gap as aspirin could potentially have a large benefit in this high-risk population. The investigator will perform a RCT to evaluate the effect of a specifically designed patient educational tool on preeclampsia knowledge and ASA adherence in pregnant women with SLE. The research efforts will improve reproductive health of SLE women and the outcomes of offsprings.

NCT ID: NCT03747159 Recruiting - Clinical trials for Lupus Erythematosus, Systemic

Synergetic B-cell Immunomodulation in SLE - 2nd Study.

SynBioSe-2
Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

In follow-up of the previous SynBioSe Study the present study is a randomized controlled trial to assess the potential of the new therapeutic approach in lupus nephritis patients. The hypothesis is that by starting therapy with belimumab (anti-BAFF), migration of tissue residing B-cells is obtained before treatment with rituximab (anti-CD20) and aims to assess the possible better reduction and seroconversion of pathogenic autoantibodies compared to the control group.

NCT ID: NCT03746197 Recruiting - Clinical trials for Lupus Erythematosus, Systemic

Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus

Start date: June 6, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether a short interactive video game device is associated with performance on standard measures of attention and problem solving in patients with systemic lupus erythematosus(SLE). The study is also designed to see if playing the video game for four weeks improves attention and problem solving in patients with SLE.

NCT ID: NCT03746028 Recruiting - Clinical trials for Systemic Lupus Erythematosus

The Lupus prEGnAnCY Cohort: An International Prospective Cohort of Lupus Pregnancies

LEGACY
Start date: June 6, 2018
Phase:
Study type: Observational [Patient Registry]

The goal is to evaluate adverse pregnancy outcomes (APO), their predictors and potential preventive therapies, such as aspirin (ASA). The investigator aims to improve the outcomes for women with SLE and offsprings. By quantifying the risk of APO conferred by clinical risk factors that can be assessed early in pregnancy (i.e. first trimester), health professionals could be better equipped to estimate the individual risk of SLE pregnancies and the need for heightened surveillance and guide counseling for prophylactic measures, including ASA. Moreover findings from this study could eventually lead to the choice and weighting of first trimester clinical factors in future clinical prediction models for APO in SLE. The investigator's research efforts will improve reproductive health of SLE women, "mitigating the damage, functional loss, and disability that result from a chronic inflammatory disorder", such as SLE.

NCT ID: NCT03742037 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Start date: December 11, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).

NCT ID: NCT03738826 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Reducing Disparities in Medication Adherence in SLE

Start date: December 2019
Phase: N/A
Study type: Interventional

This is a pilot study to assess the feasibility of a multi-level intervention to improve medication adherence in patients with systemic lupus erythematosus